Business Wire

OpenGate Capital Announces Acquisition of Majority Interest in InRule Technology, Inc.

19.8.2019 15:00:00 EEST | Business Wire | Press release

Share

OpenGate Capital, a global private equity firm, announced today that it has acquired InRule Technology, Inc. (“InRule”), a market-leading decision management platform and business rules management system (BRMS). OpenGate is pleased to partner with the co-founders of InRule to continue innovation and leadership in the decision management market. This transaction marks the fifth investment completed in 2019 through OpenGate Capital’s second institutional fund. Financial terms were not disclosed.

InRule software powers mission-critical decisions for enterprise and government customers. InRule provides an end-to-end, fully auditable platform that acts as a “single source of truth” for enterprises processing complex business rules and decision workflows. Its decision platform drives significant and quantifiable business value across a variety of use cases, including insurance eligibility, mortgage qualification, risk rating and fraud reduction, regulatory compliance, healthcare claims processing and CPQ calculations. InRule has diverse, global and long-standing relationships with more than 400 customers across a variety of industries, including financial services, public sector, IT and business services, healthcare and insurance. Headquartered in Chicago, Illinois and founded in 2002, InRule will continue to be led by Co-Founder and CEO Rik Chomko; Co-Founder and CTO Loren Goodman; and a team of industry veterans.

“We are pleased to partner with OpenGate, a global private equity firm that shares our goal to be the global leader in the decision management market,” said Rik Chomko, InRule Co-Founder and CEO. "InRule remains deeply committed to the markets we serve, and we now have greater flexibility to invest in our customers, technology, people and future. I am proud of our employees, and all that we have accomplished together; we are transforming the way complex decisions are managed by the enterprise. InRule has never been better positioned for success.”

Andrew Nikou, OpenGate Capital’s founder and CEO, commented, “InRule is an exciting investment for OpenGate when we consider the vital nature of decision automation in today’s increasingly complex world. InRule’s unique ability to process complex logic and vast amounts of data is critical at a time when governance, compliance and digital transformation are vital to any organization’s success. OpenGate’s investment in InRule is a tremendous point of pride and we welcome the business into our portfolio.”

OpenGate Capital sourced InRule through its global origination team led by Joshua Adams, Managing Director – Business Development; and Rafael Baron, Vice President – Business Development. From the firm’s Los Angeles office, the following team members are responsible for negotiating and overseeing the investment: Robert Young, Principal – M&A; and Paul Bridwell, Managing Director – Operations.

The acquisition of InRule follows the recently completed acquisitions of Duraco from Essentra, Sargent and Greenleaf from Stanley Black & Decker, SMAC from Colas Group, and Fiven from Saint-Gobain.

About OpenGate Capital

Founded in 2005, OpenGate Capital is a global private equity firm that strives to acquire and optimize lower middle market businesses throughout North America and Europe with a strategic focus on operational improvement, innovation and growth. OpenGate is headquartered in Los Angeles and Paris and has a seasoned in-house team of professionals overseeing the entire lifecycle of each investment. To learn more about OpenGate, please visit www.opengatecapital.com.

About InRule Technology, Inc.

InRule Technology® enables enterprises to understand and automate decisions with unparalleled speed, agility, accuracy and transparency. IT and business personnel rely on InRule’s Decision Platform and Business Rules Management System (BRMS) to increase productivity, grow revenue and enhance customer service. With its ‘author first’ approach, InRule empowers both technical and business rule authors to write and manage rules. From on-premises, to the cloud and via mobile, InRule allows organizations to run rules anywhere for extreme flexibility and scalability. More than 400 InRule User Community members depend on InRule to reduce development and change cycles by 90 percent for their mission critical systems and customer-facing applications. InRule has been delivering measurable business and IT results in high-performance environments since 2002. For more information visit www.inrule.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

OpenGate Media Contacts
Alanna Chaffin
Email: achaffin@opengatecapital.com
Telephone: +1 (310) 432-7000

Mike Sitrick
Sitrick & Company
Email: Mike_Sitrick@sitrick.com
Telephone: (310) 788-2850

OpenGate Business Development Contacts
Joshua Adams
Email: jadams@opengatecapital.com
Telephone: +1 (310) 432-7000

Rafael Baron
Email: rbaron@opengatecapital.com
Telephone: +1 (310) 432-7000

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 23:30:00 EET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Multi-Color Corporation Receives Court Approval of First Day Motions4.2.2026 22:30:00 EET | Press release

Multi-Color Corporation (“MCC” or the “Company”), a global leader in prime label solutions, today announced that it has received approval from the U.S. Bankruptcy Court for the District of New Jersey (the “Court”) for first day relief related to its prepackaged Chapter 11 filed on January 29, 2026. The approved relief affirms that the Company will operate in the normal course, pay all trade vendors and suppliers in full, and maintain a strong liquidity position during the restructuring. As part of this relief, the Court granted MCC immediate access to $125 million of $250 million in debtor-in-possession (“DIP”) new money financing, provided by certain holders of MCC’s secured first lien debt and its equity sponsor, CD&R. This funding will capitalize the business through the initial stages of the prepackaged Chapter 11 process. The Court also granted MCC authority to pay trade vendors and suppliers in full in the ordinary course, maintain wages and benefits without interruption, satisfy

InterSystems Honored with Four 2026 Best in KLAS Awards4.2.2026 19:00:00 EET | Press release

InterSystems, a creative data technology provider powering more than one billion health records globally, today announced it has received four Global 2026 Best in KLAS awards. The company earned a #1 ranking for Acute Care EHR in Asia, Oceania, and France, as well as for Shared Care Records in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204241673/en/ InterSystems earns four Best in KLAS awards for 2026 Best in KLAS is KLAS Research’s annual recognition of top-performing healthcare technology and services solutions, based entirely on feedback from healthcare provider organizations. Awards are given within defined software and services market segments evaluated by KLAS Research using a standardized methodology that reflects customer experience and performance. In addition to U.S. market segments, KLAS also recognizes top-performing solutions through its Global (Non-U.S.) Best in KLAS Awards, which are based on fe

Onego Bio Strengthens Board with Appointment of Dr. Antti Vasara4.2.2026 17:00:00 EET | Press release

Onego Bio, the food ingredient company producing non-animal egg protein through precision fermentation, today announced that Dr. Antti Vasara has joined its board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204881159/en/ Dr. Antti Vasara Dr. Vasara brings more than 25 years of global experience in science, technology, and commercial strategy. Most recently, he served as President and CEO of VTT Technical Research Centre of Finland, where he led one of Europe’s foremost deep tech research organizations. His distinguished career spans senior leadership roles in industry and innovation policy—including impactful work with Nokia and strategic contributions to European research and development initiatives. “Antti is one of the most respected leaders in science and innovation,” said Maija Itkonen, CEO of Onego Bio. “His deep understanding of technology commercialization and ecosystem level strategy will be inva

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye